Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 1
2016 5
2017 5
2018 3
2019 2
2020 3
2021 3
2022 3
2023 12
2024 6
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.
Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar SN. Dowlati A, et al. Among authors: sullivan ig. J Thorac Oncol. 2025 Jun;20(6):799-808. doi: 10.1016/j.jtho.2024.12.028. Epub 2025 Jan 2. J Thorac Oncol. 2025. PMID: 39755168 Free article. Clinical Trial.
Epidermolysis bullosa acquisita induced by atezolizumab.
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: sullivan i. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203. Epub 2023 Sep 1. J Dtsch Dermatol Ges. 2023. PMID: 37658659 No abstract available.
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
Guckenberger M, Opitz I, Dellaporta T, Curioni-Fontecedro A, Frauenfelder T, Ribi K, Cerciello F, Sullivan I, Hendriks L, Dorta M, Callejo A, Aerts J, Addeo A, Dingemans AC, Pasello G, Provencio M, de Marinis F, Mederos-Alfonso N, Roschitzki-Voser H, Ruepp B, Haberecker M, Kammler R, Dafni U, Peters S, Stahel R; ETOP 14-18 CHESS collaborators. Guckenberger M, et al. Among authors: sullivan i. Lung Cancer. 2025 Jun;204:108553. doi: 10.1016/j.lungcan.2025.108553. Epub 2025 Apr 21. Lung Cancer. 2025. PMID: 40311307 Clinical Trial.
[Epidermolysis bullosa acquisita ausgelöst durch Atezolizumab].
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: sullivan i. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203_g. J Dtsch Dermatol Ges. 2023. PMID: 37946658 German. No abstract available.
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study.
Piedra A, Martínez-Recio S, Hernández A, Morán T, Arriola E, Recuero-Borau J, Cobo M, Cordeiro P, Mosquera J, Fernández M, García-Campelo R, Calles A, Álvarez R, Zapata-García M, Isla D, Callejo A, Iranzo P, Serra-López J, Barba A, Sullivan I, Felip E, Majem M. Piedra A, et al. Among authors: sullivan i. Front Oncol. 2024 Dec 17;14:1510278. doi: 10.3389/fonc.2024.1510278. eCollection 2024. Front Oncol. 2024. PMID: 39741981 Free PMC article.
46 results